IONS

Ionis Pharmaceuticals (IONS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

The treatment targets the SCN1A gene, which helps the brain produce a protein that controls electrical activity and prevents seizures

Hibsago is viewed as a potential “functional cure” for chronic infections and an important part of the British drugmaker’s goal of reaching £40 billion in annual revenue by 2031.

Recently published Severe Hypertriglyceridemia Market Insights report includes a comprehensive understanding of current treatment practices, severe hypertriglyceridemia emerging drugs, market share of individual therapies, and current and forecasted market…

Is ALNY a good stock to buy? We came across a bullish thesis on Alnylam Pharmaceuticals, Inc. on Astute Optics – US’s Substack. The thesis was published on September 11th, when the stock was trading at $248.68, and ALNY lost 8.70% since then.

The sell-offs for both of these beaten-down biotech stocks appear to be overdone.

Ionis Pharmaceuticals (IONS) has been drawing attention after a sharp pullback, with the share price down about 24% over the past month and roughly 26% in the past 3 months. Recent trading paints a mixed picture for Ionis Pharmaceuticals.

Ionis Pharmaceuticals has seen its share price fall sharply this year, which naturally raises a question for holders and prospective buyers.

Ionis Pharmaceuticals has had a rough run so far this year, even as fresh clinical results have put its drug pipeline in the spotlight.